{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T02:05:15Z","timestamp":1694397915564},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>We describe the case of a pediatric patient on azathioprine therapy with previously undiagnosed homozygote thiopurine S-methyltransferase (TPMT) deficiency, resulting in myelotoxic thiopurine metabolite levels. The patient was successfully treated with a very low azathioprine dose of 50 mg once a week (4% of standard dose), guided by frequent thiopurine metabolite measurement and a close clinical surveillance. We demonstrate that azathioprine therapy still might be an effective and safe therapeutic option in pediatric thiopurine S-methyltransferase\u2013deficient IBD patients.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000366","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T17:04:00Z","timestamp":1481216640000},"page":"1-4","source":"Crossref","is-referenced-by-count":4,"title":["Azathioprine Therapy in a Pediatric TPMT-Deficient Patient\u2014Still an Option"],"prefix":"10.1097","volume":"39","author":[{"given":"S. A. W.","family":"van Moorsel","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Sittard-Geleen;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Bevers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Zuyderland Medical Centre, Heerlen; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Meurs","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Zuyderland Medical Centre, Heerlen; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. K.","family":"van Rossum","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Heerlen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Hooymans","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Sittard-Geleen;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. R.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Sittard-Geleen;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MPG.0b013e3182662233","article-title":"Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines","volume":"55","author":"Turner","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/138161210790112773","article-title":"Pharmacogenetics of thiopurines in inflammatory bowel disease","volume":"16","author":"Derijks","year":"2010","journal-title":"Curr Pharm Des."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1994.tb04314.x","article-title":"Thiopurine methyltransferase activity in a French population: HPLC assay conditions and effects of drugs and inhibitors","volume":"38","author":"Jacques-Aigrain","year":"1994","journal-title":"Br J Clin Pharmacol."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007691-200406000-00016","article-title":"Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy","volume":"26","author":"Derijks","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical pharmacokinetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bcp.12226","article-title":"Implementation of TPMT testing","volume":"77","author":"Lennard","year":"2013","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.crohns.2009.02.002","article-title":"Safe 6-thioguanine therapy of a TPMT deficient Crohn's disease patient by using therapeutic drug monitoring","volume":"3","author":"Mares","year":"2009","journal-title":"J Crohns Colitis."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/gut.52.1.140","article-title":"Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine","volume":"52","author":"Kaskas","year":"2003","journal-title":"Gut"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2005.02474.x","article-title":"Two cases of thiopurine methyltransferase (TPMT) deficiency\u2014a lucky save and a near miss with azathioprine","volume":"62","author":"Gardiner","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3349\/ymj.2013.54.6.1545","article-title":"Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT*3C","volume":"54","author":"Lee","year":"2013","journal-title":"Yonsei Med J."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201702000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:00:55Z","timestamp":1692050455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201702000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000366","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}